PURPOSE: The purpose of this study was to investigate the biodistribution of mature dendritic cells (DCs) injected by various routes, during a cell therapy protocol. METHODS: In the context of a vaccine therapy protocol for melanoma, DCs matured with Ribomunyl and interferon-gamma were labelled with( 111)In-oxine and injected into eight patients along various routes: afferent lymphatic vessel (IL) (4 times), lymph node (IN) (5 times) and intradermally (ID) (6 times). RESULTS: Scintigraphic investigations showed that the IL route allowed localisation of 80% of injected radioactivity in eight to ten nodes. In three cases of IN injection, the entire radioactivity stagnated in the injected nodes, while in two cases, migration to adjacent nodes was observed. This migration was detected rapidly after injection, as with IL injections, suggesting that passive transport occurred along the physiological lymphatic pathways. In two of the six ID injections, 1-2% of injected radioactivity reached a proximal lymph node. Migration was detectable in the first hour, but increased considerably after 24 h, suggesting an active migration mechanism. In both of the aforementioned cases, DCs were strongly CCR7-positive, but this feature was not a sufficient condition for effective migration. In comparison with DCs matured with TNF-alpha, IL-1beta, IL-6 and PGE2, our DCs showed a weaker in vitro migratory response to CCL21, despite comparable CCR7 expression, and higher allostimulatory and TH1 polarisation capacities. CONCLUSION: The IL route allowed reproducible administration of specified numbers of DCs. The IN route sometimes yielded fairly similar results, but not reproducibly. Lastly, we showed that DCs matured without PGE2 that have in vitro TH1 polarisation capacities can migrate to lymph nodes after ID injection.
PURPOSE: The purpose of this study was to investigate the biodistribution of mature dendritic cells (DCs) injected by various routes, during a cell therapy protocol. METHODS: In the context of a vaccine therapy protocol for melanoma, DCs matured with Ribomunyl and interferon-gamma were labelled with( 111)In-oxine and injected into eight patients along various routes: afferent lymphatic vessel (IL) (4 times), lymph node (IN) (5 times) and intradermally (ID) (6 times). RESULTS: Scintigraphic investigations showed that the IL route allowed localisation of 80% of injected radioactivity in eight to ten nodes. In three cases of IN injection, the entire radioactivity stagnated in the injected nodes, while in two cases, migration to adjacent nodes was observed. This migration was detected rapidly after injection, as with IL injections, suggesting that passive transport occurred along the physiological lymphatic pathways. In two of the six ID injections, 1-2% of injected radioactivity reached a proximal lymph node. Migration was detectable in the first hour, but increased considerably after 24 h, suggesting an active migration mechanism. In both of the aforementioned cases, DCs were strongly CCR7-positive, but this feature was not a sufficient condition for effective migration. In comparison with DCs matured with TNF-alpha, IL-1beta, IL-6 and PGE2, our DCs showed a weaker in vitro migratory response to CCL21, despite comparable CCR7 expression, and higher allostimulatory and TH1 polarisation capacities. CONCLUSION: The IL route allowed reproducible administration of specified numbers of DCs. The IN route sometimes yielded fairly similar results, but not reproducibly. Lastly, we showed that DCs matured without PGE2 that have in vitro TH1 polarisation capacities can migrate to lymph nodes after ID injection.
Authors: S M Barratt-Boyes; M I Zimmer; L A Harshyne; E M Meyer; S C Watkins; S Capuano; M Murphey-Corb; L D Falo; A D Donnenberg Journal: J Immunol Date: 2000-03-01 Impact factor: 5.422
Authors: Elke Scandella; Ying Men; Daniel F Legler; Silke Gillessen; Ladislav Prikler; Burkhard Ludewig; Marcus Groettrup Journal: Blood Date: 2003-10-30 Impact factor: 22.113
Authors: Thomas Luft; Michael Jefford; Petra Luetjens; Tracey Toy; Hubertus Hochrein; Kelly-Anne Masterman; Charlie Maliszewski; Ken Shortman; Jonathan Cebon; Eugene Maraskovsky Journal: Blood Date: 2002-08-15 Impact factor: 22.113
Authors: Beatrice Schuler-Thurner; Erwin S Schultz; Thomas G Berger; Georg Weinlich; Susanne Ebner; Petra Woerl; Armin Bender; Bernadette Feuerstein; Peter O Fritsch; Nikolaus Romani; Gerold Schuler Journal: J Exp Med Date: 2002-05-20 Impact factor: 14.307
Authors: Alfonso MartIn-Fontecha; Silvia Sebastiani; Uta E Höpken; Mariagrazia Uguccioni; Martin Lipp; Antonio Lanzavecchia; Federica Sallusto Journal: J Exp Med Date: 2003-08-18 Impact factor: 14.307
Authors: David W Mullins; Stacey L Sheasley; Rebecca M Ream; Timothy N J Bullock; Yang-Xin Fu; Victor H Engelhard Journal: J Exp Med Date: 2003-10-06 Impact factor: 14.307
Authors: Rémi J Creusot; Shahriar S Yaghoubi; Pearl Chang; Justine Chia; Christopher H Contag; Sanjiv S Gambhir; C Garrison Fathman Journal: Blood Date: 2009-04-10 Impact factor: 22.113
Authors: Shinji Toki; Reed A Omary; Kevin Wilson; John C Gore; R Stokes Peebles; Wellington Pham Journal: Nanomedicine Date: 2013-06-06 Impact factor: 5.307